Core Insights - The company reported third-quarter revenue of 39.76 million yuan, representing a year-on-year increase of 22.63% [1] - The net profit for the third quarter was a loss of 4.64 million yuan [1] - For the first three quarters, the company achieved revenue of 112 million yuan, reflecting a year-on-year growth of 21.48% [1] - The net profit for the first three quarters was a loss of 28.86 million yuan [1]

Group 1 - The company will hold a performance briefing on October 24, 2025, from 15:00 to 16:00 [2][3] - The briefing will take place at the Shanghai Securities News and China Securities Network Roadshow Center, accessible online [2][3] - Investors can submit questions via email to the company's designated address by October 23, 2025, at 18:00 [2][4] Group 2 - Key participants in the briefing will include the Chairman and General Manager, Mr. Zhu Huaxing, and the Secretary of the Board, Mr. Wang Duqiang [3] - The company aims to provide comprehensive insights into its operational performance and development strategy during the briefing [2] - After the briefing, investors can access the main content and details of the event through the Shanghai Securities News and China Securities Network Roadshow Center [5]

二、说明会召开的时间、地点和方式 证券代码：688137 证券简称：近岸蛋白 公告编号：2025-043 苏州近岸蛋白质科技股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、说明会类型 苏州近岸蛋白质科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 28 日在上海证券交易所网站（www.sse.com.cn）披露了《2025 年半年度报告》 及《2025 年半年度报告摘要》。为便于广大投资者更加全面深入地了解公司经 营业绩、发展战略等情况，公司定于 2025 年 10 月 24 日（星期五）15:00-16:00 在上海证券报•中国证券网路演中心（https://roadshow.cnstock.com/）举办 2025 年半年度网上业绩说明会，与投资者进行沟通和交流，广泛听取投资者的意见和 建议。 会议召开时间：2025 年 10 月 24 日（星期五）15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 报 · 中 国 ...

一、募集资金基本情况 （一）募集资金金额、资金到位情况 国联民生证券承销保荐有限公司 关于苏州近岸蛋白质科技股份有限公司 使用暂时闲置募集资金进行现金管理的核查意见 国联民生证券承销保荐有限公司（下简称"国联民生承销保荐"或"保荐机 构"）作为苏州近岸蛋白质科技股份有限公司（以下简称"近岸蛋白"或"公司"） 首次公开发行股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管 理办法》《上市公司募集资金监管规则》《上海证券交易所科创板股票上市规则》 《上海证券交易所科创板上市公司自律监管指引第1号——规范运作》等相关法 律法规及规范性文件的规定，对近岸蛋白使用暂时闲置募集资金进行现金管理进 行了核查，具体情况如下： 经中国证券监督管理委员会于 2022 年 7 月 25 日出具的《关于同意苏州近岸 蛋白质科技股份有限公司首次公开发行股票注册的批复》（证监许可[2022]1626 号）批准，公司首次公开发行人民币普通股（A 股）股票（以下简称"本次发行"） 17,543,860 股，每股发行价格为人民币 106.19 元，募集资金总额为人民币 186,298.25 万元；扣除发行费用后实际的募集资金净额为人民 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 ■ 公司本次发行的募集资金拟投资项目及使用计划如下： 单位：人民币 万元 苏州近岸蛋白质科技股份有限公司 关于使用暂时闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 苏州近岸蛋白质科技股份有限公司（以下简称"公司"或"近岸蛋白"）于2025年10月13日召开第二届董事 会第十三次临时会议、第二届监事会第十次临时会议，审议通过了《关于使用暂时闲置募集资金进行现 金管理的议案》，同意公司在确保不影响募集资金投资项目建设和募集资金使用以及公司正常业务开展 的情况下,使用最高余额不超过人民币8亿元（包含本数）的暂时闲置募集资金购买安全性高、流动性 好、期限不超过12个月（含）的投资产品（包括但不限于协定性存款、结构性存款、定期存款、通知存 款、大额存单等）。在上述额度内,资金可以滚动使用,使用期限自董事会审议通过之日起12个月内有 效。 董事会授权公司管理层在授权额度和期限内行使现金管理投资决策权并签署相关合同文件，具体事项由 公司财务部负责组织实施 ...

格隆汇10月15日丨近岸蛋白(688137.SH)公布，公司计划使用最高余额不超过人民币8亿元（包含本数） 的暂时闲置募集资金进行现金管理，在上述额度内,资金可以滚动使用,使用期限自董事会审议通过之日 起12个月内有效。 ...

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-042 苏州近岸蛋白质科技股份有限公司 关于使用暂时闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州近岸蛋白质科技股份有限公司（以下简称"公司"或"近岸蛋白"）于 2025 年 10 月 13 日召开第二届董事会第十三次临时会议、第二届监事会第十次临 时会议，审议通过了《关于使用暂时闲置募集资金进行现金管理的议案》，同意 公司在确保不影响募集资金投资项目建设和募集资金使用以及公司正常业务开展 的情况下,使用最高余额不超过人民币 8 亿元（包含本数）的暂时闲置募集资金购 买安全性高、流动性好、期限不超过 12 个月（含）的投资产品（包括但不限于协 定性存款、结构性存款、定期存款、通知存款、大额存单等）。在上述额度内,资 金可以滚动使用,使用期限自董事会审议通过之日起 12 个月内有效。 董事会授权公司管理层在授权额度和期限内行使现金管理投资决策权并签署 相关合同文件，具体事项由公司财务部负责组织实施。上述事项在公司董事会审 批 ...

格隆汇10月14日丨近岸蛋白(688137.SH)公布，2025 年 10 月 13 日，公司收到股东发来的《关于股份减 持结果的告知函》，股东菏泽乔贝和上海普近通过集中竞价交易方式合计减持公司股份31.41万股，占 公司总股本比例为 0.4476%。本次减持计划已实施完毕。 ...

Core Insights - The stock of Nearshore Protein experienced a decline of 1.46% on October 13, with a trading volume of 13.18 million yuan [1] - The company reported a net financing outflow of 2.93 million yuan on the same day, with total financing and securities lending balance at 69.15 million yuan [1] Financing and Trading Activity - On October 13, Nearshore Protein had a financing buy-in of 1.55 million yuan, while the current financing balance is 69.15 million yuan, accounting for 5.05% of the circulating market value, which is below the 40th percentile level over the past year, indicating a low position [1] - There were no shares sold or repaid in the securities lending market on October 13, with the lending balance also at zero, suggesting a high position relative to the 90th percentile level over the past year [1] Company Overview - Nearshore Protein, established on September 7, 2009, and listed on September 29, 2022, is located in Suzhou, Jiangsu Province [1] - The company's main business includes the research, production, and sales of target and factor proteins, recombinant antibodies, enzymes, and reagents, along with related technical services [1] - The revenue composition is as follows: target and factor proteins 58.04%, enzymes and reagents 25.63%, CRO services 11.87%, recombinant antibodies 2.67%, and others 1.79% [1] Financial Performance - For the period from January to June 2025, Nearshore Protein achieved a revenue of 72.09 million yuan, representing a year-on-year growth of 20.85%, while the net profit attributable to the parent company was -24.22 million yuan, a decrease of 172% year-on-year [2] - Since its A-share listing, the company has distributed a total of 70.18 million yuan in dividends [3] Shareholder Information - As of August 20, the number of shareholders for Nearshore Protein was 6,459, a decrease of 4.41% from the previous period, with an average of 5,058 circulating shares per person, an increase of 4.61% [2] - As of June 30, 2025, notable institutional shareholders include Huashang LeXiang Flexible Allocation Mixed A, which increased its holdings by 41,500 shares, and several new institutional shareholders have entered the top ten list [3]

Group 1 - The National Development and Reform Commission will hold a press conference to discuss the achievements of grain circulation reform during the 14th Five-Year Plan period [1] - Microsoft has stopped providing security updates and technical support for Windows 10, increasing the risk of cyberattacks for users [2] - A total of 2.15 billion yuan worth of restricted shares will be unlocked today, with major contributions from Zhaoyi Innovation and Dingyang Technology [3] Group 2 - 15 companies have disclosed their stock repurchase progress, with significant amounts proposed by several firms, including China Merchants Industry and Jiuan Medical [4] - Economic data such as the Eurozone ZEW Economic Sentiment Index and the UK's unemployment rate for September will be released [5]